Graft Versus Host Disease

Stella K. Kim; Rosa Y. Kim; M. Reza Dana

doi:10.1007/978-3-030-42634-7_312

Graft Versus Host Disease

Stella K. Kim, Rosa Y. Kim, M. Reza Dana

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Graft versus host disease (GVHD) is a major complication of allogeneic blood and marrow transplantation (BMT) that remains as a common cause of morbidity and mortality after successful hematopoietic stem cell transplantation (HSCT) [1-5]. GVHD has been recognized since the early days of BMT, which was pioneered by Dr. Ed Thomas in the late 1950s [6] for which he received the Nobel Prize in Medicine. Unlike other forms of immunologic rejection in which the host reacts against the foreign cells of the graft, GVHD results from the reaction of transplanted immunocompetent cells against the host, hence its name graft (donor cells) vs. host (patient) disease. GVHD has long been recognized in animal systems, manifested by erythroderma, generalized wasting, diarrhea, jaundice, and ultimately death [7, 8].

Original language	English (US)
Title of host publication	Albert and Jakobiec's Principles and Practice of Ophthalmology
Subtitle of host publication	Fourth Edition
Publisher	Springer International Publishing
Pages	7557-7579
Number of pages	23
ISBN (Electronic)	9783030426347
ISBN (Print)	9783030426330
DOIs	https://doi.org/10.1007/978-3-030-42634-7_312
State	Published - Jan 1 2022

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-3-030-42634-7_312

Cite this

@inbook{2cb1ce38e99f45f3b8a537442d3058b2,

title = "Graft Versus Host Disease",

abstract = "Graft versus host disease (GVHD) is a major complication of allogeneic blood and marrow transplantation (BMT) that remains as a common cause of morbidity and mortality after successful hematopoietic stem cell transplantation (HSCT) [1-5]. GVHD has been recognized since the early days of BMT, which was pioneered by Dr. Ed Thomas in the late 1950s [6] for which he received the Nobel Prize in Medicine. Unlike other forms of immunologic rejection in which the host reacts against the foreign cells of the graft, GVHD results from the reaction of transplanted immunocompetent cells against the host, hence its name graft (donor cells) vs. host (patient) disease. GVHD has long been recognized in animal systems, manifested by erythroderma, generalized wasting, diarrhea, jaundice, and ultimately death [7, 8].",

author = "Kim, {Stella K.} and Kim, {Rosa Y.} and Dana, {M. Reza}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-030-42634-7_312",

language = "English (US)",

isbn = "9783030426330",

pages = "7557--7579",

booktitle = "Albert and Jakobiec's Principles and Practice of Ophthalmology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Graft Versus Host Disease

AU - Kim, Stella K.

AU - Kim, Rosa Y.

AU - Dana, M. Reza

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Graft versus host disease (GVHD) is a major complication of allogeneic blood and marrow transplantation (BMT) that remains as a common cause of morbidity and mortality after successful hematopoietic stem cell transplantation (HSCT) [1-5]. GVHD has been recognized since the early days of BMT, which was pioneered by Dr. Ed Thomas in the late 1950s [6] for which he received the Nobel Prize in Medicine. Unlike other forms of immunologic rejection in which the host reacts against the foreign cells of the graft, GVHD results from the reaction of transplanted immunocompetent cells against the host, hence its name graft (donor cells) vs. host (patient) disease. GVHD has long been recognized in animal systems, manifested by erythroderma, generalized wasting, diarrhea, jaundice, and ultimately death [7, 8].

AB - Graft versus host disease (GVHD) is a major complication of allogeneic blood and marrow transplantation (BMT) that remains as a common cause of morbidity and mortality after successful hematopoietic stem cell transplantation (HSCT) [1-5]. GVHD has been recognized since the early days of BMT, which was pioneered by Dr. Ed Thomas in the late 1950s [6] for which he received the Nobel Prize in Medicine. Unlike other forms of immunologic rejection in which the host reacts against the foreign cells of the graft, GVHD results from the reaction of transplanted immunocompetent cells against the host, hence its name graft (donor cells) vs. host (patient) disease. GVHD has long been recognized in animal systems, manifested by erythroderma, generalized wasting, diarrhea, jaundice, and ultimately death [7, 8].

UR - http://www.scopus.com/inward/record.url?scp=85158974784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85158974784&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-42634-7_312

DO - 10.1007/978-3-030-42634-7_312

M3 - Chapter

AN - SCOPUS:85158974784

SN - 9783030426330

SP - 7557

EP - 7579

BT - Albert and Jakobiec's Principles and Practice of Ophthalmology

PB - Springer International Publishing

ER -

Graft Versus Host Disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this